Navigation Links
EpiVax Reports $5.2 Million for New Q Fever Vaccine Means There is Hope for Vaccines On Demand
Date:6/11/2015

PROVIDENCE, R.I., June 11, 2015 /PRNewswire/ -- EpiVax reports today that the Defense Threat Reduction Agency (DTRA) is investing $5.2 Million for the development of a new type of vaccine against Q fever. Academic and industry organizations from around the world, led by Mark Poznansky of the Vaccine and Immunotherapy Center (VIC) and Massachusetts General Hospital and Annie De Groot of EpiVax (Providence, Rhode Island) have joined forces to focus on rapid vaccine development for emerging infectious disease. The VaxCelerate consortium includes collaborators from Colorado State University in Fort Collins; InnatOss Laboratories in Oss, the Netherlands and Yale University in New Haven, Connecticut.

EpiVax contributes first-in-class immunoinformatics tools to speed the pace of vaccine development and provide rapid clues about the likelihood of success in human trials. "EpiVax has worked hard to be at the forefront of the 'vaccines on demand' concept.  Their selection as a partner in this project recognizes their leadership in terms of developing safer, more efficient vaccines and improving our national biodefense rapid response capabilities," stated U.S. Senator Jack Reed (D-RI), the Ranking Member of the Armed Services Committee.

Following a delayed response to the H1N1 flu in 2009, the U.S. federal government has made major investments in rapid vaccine manufacturing approaches. The VaxCelerate effort received early funding from the Defense Advanced Research Programs Agency (DARPA) to integrate cutting-edge technologies into an end-to-end vaccine development process. The consortium was able to successfully develop and test a new vaccine for Lassa fever in 120 days, starting only from genomic data on the virus. The current DTRA-funded project focuses on the development of an RNA-based vaccine that will promote protective responses against the Q fever bacteria without the potential safety issues that prevent existing vaccine candidates from receiving US regulatory approval for use in humans.

About EpiVax
EpiVax is a biotechnology company based in Providence, Rhode Island with expertise in immunology, immunoinformatics, immunogenicity screening, deimmunization, and immune modulation. EpiVax leverages computational tools to engineer safer, more effective therapeutic proteins and rapidly design protective and efficacious new vaccines.
http://www.epivax.com/

About Q Fever
Q fever is a worldwide disease caused by the bacteria Coxiella burnetii. Humans are susceptible to the disease, and few organisms may be required to cause infection.
http://www.cdc.gov/qfever/

CONTACT:
Steven Vessella
401-272-2123
svessella@epivax.com

Logo - http://photos.prnewswire.com/prnh/20121116/NE15175LOGO


'/>"/>
SOURCE EpiVax
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Xencor Reports Complete Data Results on XmAb5871 Program at European League Against Rheumatism (EULAR) 2015 Annual Meeting
2. Cantel Medical Reports Results For The Third Quarter Ended April 30, 2015
3. VirtualScopics, Inc. Reports Voting Results At Annual Meeting Of Shareholders; All Board Seats Renewed
4. Cyberonics Reports Quarter And Annual Results
5. U.S. Pet Medications Market to Reach $10 Billion by 2018, Remains Hotbed for Intense Competition, finds Reports by Packaged Facts and the FTC
6. MGC Diagnostics Corporation Reports Fiscal 2015 Second Quarter Results
7. Global Sanitation Fund Reports Major Sanitation & Hygiene Advances for Seven Million People in 13 Countries
8. Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015
9. BioLight Reports First Quarter 2015 Financial Results
10. TV Mesh Lawsuit Funding Firm, Fair Rate Funding, Reports Delaware Woman Awarded $100 Million Against Boston Scientific in Pelvic Mesh Verdict.
11. Essa Pharma Inc. Reports Second Quarter 2015 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2019)... CYPRESS, Calif. (PRWEB) , ... March 25, 2019 ... ... Leandra Hernández , along with Dr. Jennifer Belding, served as co-editors on the ... published through Lexington Press . , With contributors from fields including ...
(Date:3/23/2019)... ... , ... Atkinson Ergonomic Solutions, Inc. has entered the hospitality market with a ... a housekeeper to safely and single-handedly raise the heaviest beds with ease. The ... and away from the wall are many. The bed will stay in the raised ...
(Date:3/20/2019)... ... March 20, 2019 , ... Developing PVC Free Medical ... has woken up to realize the hidden health hazards associated with PVC-based medical ... toxic effects and perilous health problems that affect the functioning of the human ...
Breaking Medicine Technology:
(Date:3/20/2019)... ... March 20, 2019 , ... ... being developed with Wi-Fi connectivity to allow portable devices to be easily moved ... monitoring, glucose monitoring, and other wearable devices for home healthcare require “always on” ...
(Date:3/20/2019)... , ... March 20, 2019 , ... GRM Information Management, ... Information Management Systems Society (HIMSS) conference in Austin, Texas on March 25 and 26. ... to learn more about GRM’s healthcare information management solutions . , GRM offers ...
(Date:3/20/2019)... IPSWICH, Mass. (PRWEB) , ... March 20, 2019 ... ... evidence-based clinical resources including Option Grid™ decision aids, has announced the ... Test for Chromosome Problems: Yes or No? and Down Syndrome Screening Test: Yes ...
(Date:3/20/2019)... ... March 20, 2019 , ... Dr. Joe Lowrance, psychologist ... for financial consultants: “Learn to practice mindfulness.” , In a white paper, ... Dr. Lowrance writes that financial advisors are discovering the power of mindfulness as ...
(Date:3/20/2019)... ... March 20, 2019 , ... VirtuOx, ... a new way to diagnose cardiac arrhythmias in the patient’s home. , The ... by utilizing mobile cardiac telemetry (MCT) in the convenience and comfort of the ...
Breaking Medicine News(10 mins):